<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>6
<FILENAME>a2107125zex-10_35.htm
<DESCRIPTION>EXHIBIT 10.35
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#03NYC3487_5">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><B>Exhibit&nbsp;10.35  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kg3487_consent_and_agreement"> </A>
<A NAME="toc_kg3487_1"> </A>
<BR></FONT><FONT SIZE=2><B>CONSENT AND AGREEMENT    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Consent And Agreement</B></FONT><FONT SIZE=2> (this "Agreement") dated December&nbsp;13, 2002 (the "Effective Date") is made by and
among American Cyanamid Company, 5 Giralda Farms, Madison, New Jersey 07940 ("ACY"), and Neurocrine Biosciences,&nbsp;Inc., 10555 Science Center Drive, San Diego, California 92121 ("Neurocrine"),
and DOV Pharmaceutical,&nbsp;Inc., 433 Hackensack Avenue, Hackensack, New Jersey 07601 ("DOV"). ACY, Neurocrine and DOV may each be referred to herein individually as a "Party" and collectively as
the "Parties". </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS</B></FONT><FONT SIZE=2>, DOV and ACY entered into a License Agreement dated May&nbsp;29, 1998 (as amended from time to time, the "License Agreement")
pursuant to which DOV was granted an exclusive license from ACY to the compound designated as CL 285,489 (the "Compound"); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS</B></FONT><FONT SIZE=2>, DOV and Neurocrine entered into a Sublicense Agreement dated June&nbsp;30, 1998 (as amended from time to time, the "Sublicense
Agreement") pursuant to which DOV sublicensed to Neurocrine its rights under the License Agreement in the Patent Rights and Know-How (each as defined in the Sublicense Agreement) to, among
other things, make and sell the Licensed Product (as defined in the Sublicense Agreement). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS</B></FONT><FONT SIZE=2>, Neurocrine desires to further sublicense the rights sublicensed to it under the Sublicense Agreement; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS</B></FONT><FONT SIZE=2>, Neurocrine and DOV would now like to amend the Sublicense Agreement, and ACY and DOV would now like to amend the License
Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>NOW THEREFORE</B></FONT><FONT SIZE=2> in consideration of the foregoing, the promises, mutual covenants and obligations set forth below, and other good and
valuable consideration, the Parties agree as follows. </FONT></P>

<P><FONT SIZE=2><B>1.&nbsp;&nbsp;&nbsp;&nbsp;LICENSE AGREEMENT.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>1.1</B></FONT></DT><DD><FONT SIZE=2>Status of License Agreement. As of the Effective Date of this Agreement, each of ACY and DOV represents and warrants that the License
Agreement is in full force and effect</FONT><FONT SIZE=2><B>.</B></FONT><FONT SIZE=2> ACY acknowledges that it has consented to DOV's entry into the Sublicense Agreement and that ACY's right of first
refusal as set forth in Section&nbsp;4.1 of the License Agreement does not apply to any additional sublicense agreements or the DOV Standby License (as defined below).
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>1.2</B></FONT></DT><DD><FONT SIZE=2><B>Amendment to Section&nbsp;1.8.</B></FONT><FONT SIZE=2> Section&nbsp;1.8 of the License Agreement is hereby amended to read as follows:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.8</FONT></DT><DD><FONT SIZE=2>"Net
Sales" means the gross amount invoiced for the Marketed Product sold by DOV and/or its Affiliates or its sublicensees (including any further sublicensees) less:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>transportation
charges or allowances, if any, included in such price;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>trade,
quantity or cash discounts, service allowances and broker's or agent's commissions, but not salaries, commissions, bonuses or other incentive pay to in-house sales
or other personnel, if any, allowed or paid;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>credits
or allowances, if any, given or made on account of price adjustments, returns, bad debts, off-invoice promotional discounts, rebates, and any or all federal, state
or local government rebates whether in existence now or enacted at any time during the term of the Agreement (e.g., HCFA or Medicaid rebates), recalls, or destruction requested or made by an
appropriate government agency; and
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD><FONT SIZE=2>any
tax, excise or governmental charge upon or measured by the sale, transportation, delivery or use of the Marketed Product, </FONT></DD></DL>
</DD></DL>
</DD></DL>
</UL>
<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5",CHK=878438,FOLIO='blank',FILE='DISK009:[03NYC7.03NYC3487]KG3487A.;8',USER='NVILLAL',CD='28-MAR-2003;22:51' -->
<A NAME="page_kg3487_1_2"> </A>
<UL>
<UL>
<UL>
<UL>
</UL>
</UL>
</UL>
</UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that in no event shall Net Sales be less than eighty percent (80%) of gross amount invoiced for the Marketed Product. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the case of discounts on "bundles" of products which include the Marketed Product, DOV, its Affiliates and its sublicensees (including further sublicensees) may, with notice to ACY,
calculate Net Sales as set forth above discounting the bona fide list price of the Marketed Product by the average percentage discount of all products of the selling party and/or its Affiliates or
sublicensees in a particular "bundle", calculated as follows: </FONT></P>
</UL>
</UL>
</UL>
<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="16%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="26%"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average percentage</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="16%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="26%"><FONT SIZE=2>discount on a</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=2>= (1-A/B)&nbsp;&times;&nbsp;100</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="16%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="26%"><FONT SIZE=2>particular "bundle"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<UL>
<UL>
<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;where
A equals the total discounted price of a particular "bundle" of products, and B equals the sum of the undiscounted bona fide list prices of each unit of every product in such
"bundle". DOV shall provide ACY documentation, reasonably acceptable to ACY, establishing such average discount with respect to each "bundle". Where the Marketed Product is also sold other than in
bundled form, the average discount as calculated above shall be applied to the undiscounted list price of the Marketed Products in the "bundle". If the Marketed Product is not sold separately and no
bona fide list price exists for the Marketed Product, the parties shall negotiate in good faith an imputed list price for the Marketed Product, and the average discount as calculated above with
respect thereto shall be applied to such imputed list price. </FONT></P>

</UL>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.3</FONT></DT><DD><FONT SIZE=2><B>Amendment to Section&nbsp;6.5.</B></FONT><FONT SIZE=2> Section&nbsp;6.5 of the License Agreement is hereby amended to read as follows: </FONT></DD></DL>
</UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5
DOV shall keep and shall obligate its sublicensees to keep accurate and complete records of all sales of Marketed Product in accordance with generally accepted accounting principles
and practices. In any agreement between DOV and a third party, DOV shall obligate such third party to allow routine audits by ACY of such third party's records relating to the Marketed Product and
shall further require such third party to likewise obligate any additional third party that enters into an agreement with the third party relating to the Marketed Product to allow routine audits by
ACY of such additional third
party's records relating to the Marketed Product. ACY, no more than one time per calendar year for each of DOV or any third party so audited, may conduct, at its own expense, at reasonable times
during normal business hours, through an accountant designated by ACY and acceptable to DOV (and its sublicensees and their sublicensees, as appropriate), an audit of the accounts contemplated above,
as well as any supporting instruments and documents, and may make copies of and extracts from such records for the sole purpose of ascertaining or verifying the correctness of the amounts remitted by
DOV hereunder. Such accountant shall be required by DOV or any sublicensee to enter into a reasonably acceptable confidentiality agreement, and in no event shall such accountants disclose to ACY or
DOV any information other than information relating to or supporting the accuracy of the payments due from DOV hereunder (and, except to the extent necessary to support sales data using bundles, in no
event information that relates to products other than the Marketed Product). Each such audit shall be limited to the records and accounts pertaining to the year on which the audit is conducted and the
immediately preceding 5 calendar years. Results in the form of a report of such audit shall be made available by ACY to DOV and to any third party that is the subject of the audit. Should such audit
reveal any discrepancies between reports made by DOV or its sublicensees and the audit exceeding 5% in favor of DOV or any third party that is </FONT></P>

</UL>
</UL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5",CHK=344430,FOLIO='2',FILE='DISK009:[03NYC7.03NYC3487]KG3487A.;8',USER='NVILLAL',CD='28-MAR-2003;22:51' -->
<A NAME="page_kg3487_1_3"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>
audited, then DOV shall pay in full the costs of such audit requested by ACY; otherwise, ACY shall bear the costs in full for the audit of the records of DOV, its Affiliates, or its sublicensees. In
the event DOV, its Affiliates or sublicensees (including further sublicensees) conducts an audit of any sublicensee selling the Marketed Product, DOV shall provide or shall cause such Affiliate or
sublicensee to provide to ACY a copy of each audit report generated in connection therewith. </FONT></P>

</UL>
</UL>
</UL>

<P><FONT SIZE=2><B>2.&nbsp;&nbsp;&nbsp;&nbsp;SUBLICENSE AGREEMENT.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.1</FONT></DT><DD><FONT SIZE=2><B>Status of Sublicense Agreement.</B></FONT><FONT SIZE=2> As of the Effective Date of this Agreement, each of DOV and Neurocrine represent and warrant to each
other that the Sublicense Agreement is in full force and effect.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.2</FONT></DT><DD><FONT SIZE=2><B>Amendment of Section&nbsp;1.10.</B></FONT><FONT SIZE=2> Section&nbsp;1.10 of the Sublicense Agreement, is hereby amended to read as follows:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.10</FONT></DT><DD><FONT SIZE=2>"Net
Sales" means the gross amount invoiced for the Licensed Product sold by Neurocrine or its Affiliate or its sublicensees (including any further sublicensees) less:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>transportation
charges or allowances, if any included in such price;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>trade,
quantity or cash discounts, service allowances and broker's or agent's commissions, but not salaries, commissions, bonuses or other incentive pay to in-house sales
or other personnel, if any, allowed or paid;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>credits
or allowances, if any, given or made on account of price adjustments, returns, bad debts, off-invoice promotional discounts, rebates, and any or all federal, state
or local government rebates whether in existence now or enacted at any time during the term of the Agreement (e.g., HCFA or Medicaid rebates), recalls, or destruction requested or made by an
appropriate government agency; and
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD><FONT SIZE=2>any
tax, excise of governmental charge upon or measured by the sale, transportation, delivery or use of the Licensed Product; </FONT></DD></DL>
</DD></DL>
</DD></DL>
</UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that in no event shall Net Sales of the Licensed Product be less than eighty percent (80%) of gross amount invoiced for the Licensed
Product. </FONT></P>

<P><FONT SIZE=2>In
the case of discounts on "bundles" of products which include the Licensed Product, Neurocrine, its Affiliates or sublicensees (including, further sublicensees) may, with written notice to DOV and
ACY calculate Net Sales as set forth above after discounting the bona fide list price of the Licensed Product by the average percentage discount of all products of the selling party and/or its
Affiliates or sublicensees in a particular "bundle", calculated as follows: </FONT></P>
</UL>
</UL>
</UL>
<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="16%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="26%"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average percentage</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="16%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="26%"><FONT SIZE=2>discount on a</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=2>= (1-A/B)&nbsp;&times;&nbsp;100</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="16%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="26%"><FONT SIZE=2>particular "bundle"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<UL>
<UL>
<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;where
A equals the total discounted price of a particular "bundle" of products, and B equals the sum of the undiscounted bona fide list prices of each unit of every product in such
"bundle". The selling party shall provide DOV and ACY documentation, reasonably acceptable to DOV, establishing such average discount with respect to each "bundle". Where the Licensed Product is also
sold other than in bundled form, the average discount as calculated above shall be applied to the undiscounted list price of the Licensed Product in the "bundle". If the Licensed Product in a "bundle"
is not sold </FONT></P>

</UL>
</UL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5",CHK=491906,FOLIO='3',FILE='DISK009:[03NYC7.03NYC3487]KG3487A.;8',USER='NVILLAL',CD='28-MAR-2003;22:51' -->
<A NAME="page_kg3487_1_4"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>
separately and no bona fide list price exists for such product or the Licensed Product, DOV and Neurocrine shall negotiate in good faith an imputed list price for the Licensed Product, and the
average discount as calculated above with respect thereto shall be applied to such imputed list price. </FONT></P>

</UL>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.3</FONT></DT><DD><FONT SIZE=2><B>Amendment of Section&nbsp;1.18</B></FONT><FONT SIZE=2>. Section&nbsp;1.18 of the Sublicense Agreement is amended to change the defined term Licensed
Product to read "Licensed Product" or "Marketed Product."
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.4</FONT></DT><DD><FONT SIZE=2><B>Amendment of Article&nbsp;1.</B></FONT><FONT SIZE=2> Article&nbsp;1 of the Sublicense Agreement is amended by adding to the end thereof the following as
new Section&nbsp;1.19:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.19</FONT></DT><DD><FONT SIZE=2><B>"Commercially Reasonable Efforts"</B></FONT><FONT SIZE=2> shall mean efforts and resources commonly used by a reasonable pharmaceutical company for a product
owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, regulatory
authority approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, the likelihood or regulatory approval given the
regulatory structure involved, the profitability of the product, alternative products and other relevant factors. </FONT></DD></DL>
</DD></DL>
<UL>
<BR>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>2.5</B></FONT></DT><DD><FONT SIZE=2><B>Amendment of Section&nbsp;3.4.</B></FONT><FONT SIZE=2> Section&nbsp;3.4 of the Sublicense Agreement is hereby amended to read as set forth below:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>3.4</B></FONT></DT><DD><FONT SIZE=2>Neurocrine shall use Commercially Reasonable Efforts to develop and commercialize the Marketed Product in all countries of the
Territory. In addition to the foregoing, if, prior to regulatory approval of a Licensed Product in the United States (a)&nbsp;Neurocrine terminates the R&amp;D Program or halts all or otherwise fails to
conduct R&amp;D Program activities directed toward development of the Marketed Product for approval in the United States for a period of 6&nbsp;months or longer in the United States (for reasons other
than regulatory constraints), DOV shall have the right to terminate this Agreement within the entire Territory, effective upon Neurocrine's receipt of written notice of termination from DOV and
(b)&nbsp;if Neurocrine terminates the R&amp;D Program with respect to any country or otherwise fails to conduct any development activities directed to any country, DOV may provide notice to Neurocrine
and Neurocrine will thereafter have 6&nbsp;months to present to DOV a commercially reasonable plan for development activities with respect to such country. If Neurocrine fails within 30&nbsp;days
to notify DOV that it intends to present such a plan or fails to present such a plan to DOV, DOV shall have the right to terminate this Agreement with respect to such country effective upon
30&nbsp;days notice. In such event, DOV will be entitled to any payments previously paid to, or which have accrued to DOV. </FONT></DD></DL>
</DD></DL>
<UL>
<BR>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>2.6</B></FONT></DT><DD><FONT SIZE=2><B>Amendment of Section&nbsp;5.2.</B></FONT><FONT SIZE=2> Section&nbsp;5.2 of the Sublicense Agreement is hereby amended by adding the following at the end of
Section&nbsp;5.2: "The parties acknowledge and agree that the Patent Rights and Know-How licensed pursuant to this Agreement justify royalty rates of differing amounts with respect to
sales of Licensed Products, which rates could be applied separately to in respect of the exercise of such Patent Rights and/or the incorporation of such Know-How, and that, if such
royalties were calculated separately, royalties relating to Patent Rights and royalties relating to Know-How would last for
different terms. Notwithstanding the foregoing, the parties have determined, for reasons of convenience, that blended royalty rates for the Patent Rights and the Know-How licensed
hereunder, as set forth above, will apply during a single royalty term, subject to adjustment only as set forth above in this Section&nbsp;5.2." </FONT></DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=4,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5",CHK=265625,FOLIO='4',FILE='DISK009:[03NYC7.03NYC3487]KG3487A.;8',USER='NVILLAL',CD='28-MAR-2003;22:51' -->
<A NAME="page_kg3487_1_5"> </A>
<UL>
<UL>
</UL>
</UL>

<P><FONT SIZE=2><B>3.&nbsp;&nbsp;&nbsp;&nbsp;SUBLICENSES AND STANDBY LICENSES.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>3.1</B></FONT></DT><DD><FONT SIZE=2><B>Additional Sublicenses.</B></FONT><FONT SIZE=2> In the event Neurocrine grants to any third party (a "Neurocrine
Sublicensee</FONT><FONT SIZE=2><B>"</B></FONT><FONT SIZE=2>) a sublicense of any of the rights granted to it under the Sublicense Agreement or such rights are further sublicensed by any Neurocrine
Sublicensee or their sublicensees, Neurocrine shall provide to each of DOV and ACY or shall cause to be provided to each of DOV and ACY a copy of each agreement in which any such sublicense is granted
which copy may be redacted (with good cause shown including a statement of the nature of the redaction) with respect to certain information confidential to the Neurocrine Sublicensee but which will be
complete and accurate with respect to provisions regarding the license of the Patent Rights and Know-How, the development or commercialization of the Licensed Product (as such term is
defined in the Sublicense Agreement), calculation of payments in respect to Patent Rights and Know-How including fees, milestones and royalty payments (but not FTE rates for development
activities or detail costs included in sales force expenses,) and diligence requirements of the Neurocrine Sublicensee, (all of which information shall be held as confidential and used only for the
purpose of this Agreement) (each an "Additional Sublicense Agreement"), within ten (10)&nbsp;business days after such Additional Sublicense Agreement is signed by the parties thereto. Any such
sublicense shall require the prior written approval of each of DOV and ACY, </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, such approval shall not be required where the sublicensee
is any of the following large pharmaceutical companies and their wholly owned subsidiaries: Abbott Laboratories, Asahi Kasei Corporation, Aventis Pharmaceuticals,&nbsp;Inc., Bristol-Myers Squibb
Company, GlaxoSmithKline, Johnson&nbsp;&amp; Johnson, Eli Lilly and Company, Merck&nbsp;&amp; Co.,&nbsp;Inc., Novartis Pharma AG, Pfizer&nbsp;Inc., Takeda Chemical Industries,&nbsp;Ltd., Yamanouchi
Pharmaceutical Co.,&nbsp;Ltd. (each, an "Approved Sublicensee"). Neurocrine shall be responsible for and shall guarantee the performance of each Neurocrine Sublicensee to whom a sublicense is
granted. Neurocrine, upon ACY's or DOV's request, shall execute and deliver to each of ACY and DOV, a written document, in form and substance reasonably acceptable to each of ACY and DOV, representing
such guarantee.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>3.2</B></FONT></DT><DD><FONT SIZE=2><B>Standby License to Neurocrine.</B></FONT><FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>If,
during the term of the Sublicense Agreement, the License Agreement is terminated or otherwise ceases to be in effect for any reason other than (i)&nbsp;expiration thereof, or
(ii)&nbsp;an uncured breach thereof by DOV which results from an act or omission on the part of Neurocrine or any of Neurocrine's Affiliates or Approved Sublicensees which would constitute tortious
interference (any such termination of the License Agreement, a "Neurocrine Non-Defaulting Termination Event"), subject to Section&nbsp;3.2(b)
below, ACY hereby grants to Neurocrine a direct license (with ACY assuming the rights and obligations of DOV as licensor) to the Compound and Licensed Product on the same terms and license grant
conditions as the Sublicense Agreement (which shall not include any payments made or obligations met by DOV prior to such direct license) including without limitation, a license with respect to Patent
Rights and Know-How (as such terms are defined in the Sublicense Agreement) (such license, the "ACY/Neurocrine Standby License"), which license shall be effective immediately (without the
need for need for notice to or action by any person) at any time that the License Agreement first terminates for reasons as set forth above in this Section&nbsp;3.2(a) (such effective time of the
ACY/Neurocrine Standby License, the "First Effective Time"). DOV hereby consents to ACY's grant of such a license to Neurocrine, provided that such consent shall not reduce the exclusivity enjoyed by
DOV under the ACY Patents and ACY Know-How beyond that which such exclusivity with respect to the Patent Rights and Know-How with respect to the Licensed Product was reduced by
DOV's grant of rights to Neurocrine prior to the First Effective Time. Notwithstanding any provision to the contrary in this Article&nbsp;3, in </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=5,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5",CHK=572558,FOLIO='5',FILE='DISK009:[03NYC7.03NYC3487]KG3487A.;8',USER='NVILLAL',CD='28-MAR-2003;22:51' -->
<A NAME="page_kg3487_1_6"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>the
event that the sublicense of the Patent Rights and Know-How granted by DOV to Neurocrine under the Sublicense Agreement is terminated by either DOV or Neurocrine, in whole or in part,
for any reason, the license granted by ACY to Neurocrine under this Section&nbsp;3.2(a) shall likewise be automatically terminated to the same extent. </FONT></P>

</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>Following
the First Effective Time, the continuation of the ACY/ Neurocrine Standby License shall be subject to Neurocrine curing all breaches of the License Agreement that remain
uncured and are capable of cure by Neurocrine at the time the License Agreement was terminated within ten (10)&nbsp;business days of the effective date of such termination. If Neurocrine fails to
cure all such breaches within such time period, the ACY/Neurocrine Standby License shall automatically be terminated at the end of such ten (10)&nbsp;business day period following notice from ACY
and delineation of the uncured breaches, subject to the provisions of this Section&nbsp;3. Except as set forth above in this Section&nbsp;3.2(b), the licenses granted by ACY to Neurocrine under
Section&nbsp;3.2(a) above shall be on the terms and conditions set forth in the Sublicense Agreement and ACY shall have all rights previously held by DOV thereunder. Following the First Effective
Time and for so long as the ACY/Neurocrine Standby License remains in effect, Neurocrine shall pay directly to ACY all royalty payments under the ACY/Neurocrine Standby License.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>As
of the First Effective Time, upon the request of either ACY or Neurocrine, each of ACY and Neurocrine shall enter into a separate written agreement reflecting the licenses granted
under this Section&nbsp;3.2 and the terms and conditions set forth in the Sublicense Agreement. </FONT></DD></DL>
<BR>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>3.3</B></FONT></DT><DD><FONT SIZE=2><B>DOV Standby License to an Approved Sublicensee.</B></FONT><FONT SIZE=2>&nbsp;
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>If
(i)&nbsp;Neurocrine enters into an Additional Sublicense Agreement with an Approved Sublicensee, and (ii)&nbsp;during the term of such Additional Sublicense Agreement the
Sublicense Agreement is terminated or otherwise ceases to be in effect for any reason other than (i)&nbsp;expiration thereof, or (ii)&nbsp;an uncured breach thereof by Neurocrine which breach
results from an act or omission on the part of any Approved Sublicensee or any of such Approved Sublicensee's Affiliates or sublicensees which would
constitute tortious interference (any such termination of the Sublicense Agreement, an "Approved Sublicensee Non-Defaulting Termination Event"), subject to Section&nbsp;3.3(b) below, DOV
hereby grants to such Approved Sublicensee a direct sublicense to the Compound and the Licensed Product on the same terms and conditions as the Sublicense Agreement (which shall not include any
payments made or obligations met by Neurocrine prior to such direct license)(including without limitation a license with respect to the Patent Rights and Know-How (as defined in the
Sublicense Agreement)) (such license, the "DOV Standby License"), which license shall be effective immediately (without the need for notice to or action by any person) at any time that the Sublicense
Agreement first terminates for reasons as set forth above in this Section&nbsp;3.3(a) (such effective time of the DOV Standby License, the "Second Effective Time"). Neurocrine hereby consents to
DOV's grant of such a license to such an Approved Sublicensee, provided that such consent shall not reduce the exclusivity enjoyed by Neurocrine under the Patent Rights and Know-How beyond
that which such exclusivity with respect to the Patent Rights and Know-How with respect to the Licensed Product was reduced by Neurocrine's grant of rights to the Approved Sublicensee
prior to the Second Effective Time.&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any provision to the contrary in this Article&nbsp;3, in the event that the sublicense of the Patent Rights and
Know-How granted by Neurocrine to an Approved Sublicensee under the Additional Sublicense Agreement is terminated by either Neurocrine the Approved Sublicensee, in whole or in part with
respect to any country or countries, for any reason, </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=6,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5",CHK=797400,FOLIO='6',FILE='DISK009:[03NYC7.03NYC3487]KG3487A.;8',USER='NVILLAL',CD='28-MAR-2003;22:51' -->
<A NAME="page_kg3487_1_7"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>the
license granted by DOV to the Approved Sublicensee under this Section&nbsp;3.2(a) shall likewise be automatically terminated to the same extent. </FONT></P>

</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>Following
the Second Effective Time, the continuation of the DOV Standby License shall be subject to the Approved Sublicensee curing all outstanding breaches of the Sublicense
Agreement that remain uncured and capable of cure by the Approved Sublicensee at the time the Sublicense Agreement was terminated within ten (10)&nbsp;business days of the effective date of such
termination and notice from DOV and delineation of the uncured breaches. If the Approved Sublicensee fails to cure all such breaches within such time period, the license to be granted by DOV to the
Approved Sublicensee under Section&nbsp;3.3(a) above shall automatically be terminated at the end of such ten (10)&nbsp;business day period. Except as set forth above in this
Section&nbsp;3.3(b), the DOV Standby License shall be on the terms and conditions (which shall not include any payments made or obligations met by Neurocrine prior to such direct license) set forth
in the Sublicense Agreement and the Approved Sublicensee shall have all of the rights and obligations previously held by Neurocrine thereunder. Following the Second Effective Time and for so long as
the DOV Standby License remains in effect, the Approved Sublicensee shall pay directly to DOV all payments and other consideration due under the DOV Standby License. Neurocrine hereby acknowledges and
agrees that all amounts paid by the Approved Sublicensee pursuant to the DOV Standby License as well as the amounts referenced in the first sentence of this Section&nbsp;3.3(b) shall be credited in
full against any sums due under the Additional Sublicense Agreement to which the Approved Sublicensee is a party. </FONT></DD></DL>
<BR>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>3.4</B></FONT></DT><DD><FONT SIZE=2><B>ACY Standby License to an Approved Sublicensee.</B></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>If
(i)&nbsp;Neurocrine enters into an Additional Sublicense Agreement with an Approved Sublicensee, and (ii)&nbsp;during the term of such Additional Sublicense Agreement the
ACY/Neurocrine Standby License Agreement is terminated, does not come into existence or otherwise ceases to exist for any reason other than (x)&nbsp;the expiration thereof, or (y)&nbsp;an uncured
breach thereof by Neurocrine which breach results from an act or omission on the part of any Approved Sublicensee or any of such Approved
Sublicensee's Affiliates or sublicensees which would constitute tortious interference (any such termination of the ACY/Neurocrine Standby License, an "Approved Sublicensee Non-Defaulting
Standby Termination Event"), then, subject to Section&nbsp;3.4(b) below, ACY hereby grants to such Approved Sublicensee a direct license to the Compound and Licensed Product on the same terms as the
ACY/Neurocrine Standby License (which shall not include any payments made or obligations met by DOV or Neurocrine prior to such direct license) (including without limitation a license with respect to
the Patent Rights and Know-How (as such terms are defined in the Sublicense Agreement)) (such license, the "Second ACY Standby License"), which license shall be effective immediately
(without the need for notice to or action by any person) at any time that the ACY/Neurocrine Standby License first terminates, does not come into existence or otherwise ceases to be in effect for
reasons as set forth above in this Section&nbsp;3.4(a) (such effective time of the Second ACY Standby License, the "Third Effective Time").&nbsp;&nbsp;&nbsp;&nbsp;Neurocrine hereby consents to DOV's grant
of such a license to such an Approved Sublicensee, it being understood that such consent shall not reduce the exclusivity with respect to the Patent Rights and Know-How with respect to the
Licensed Product enjoyed by Neurocrine under the Patent Rights and Know-How beyond that which such exclusivity was reduced by Neurocrine's grant of rights to the Approved Sublicensee prior
to the Second Effective Time. Notwithstanding any provision to the contrary in this Article&nbsp;3, in the event that the sublicense of the Patent Rights and Know-How granted by
Neurocrine to such Approved Sublicensee under the Additional Sublicense Agreement is terminated by either </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=7,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5",CHK=740027,FOLIO='7',FILE='DISK009:[03NYC7.03NYC3487]KG3487A.;8',USER='NVILLAL',CD='28-MAR-2003;22:51' -->
<A NAME="page_kg3487_1_8"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>Neurocrine
or the Additional Sublicensee, in whole or in part with respect to any country or countries, for any reason, the license granted by ACY to the Approved Sublicensee under this
Section&nbsp;3.4(a) shall likewise be automatically terminated to the same extent. </FONT></P>

</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>In
the event of an Approved Sublicensee Non-Defaulting Standby Termination Event, the licenses to be granted by ACY to the Approved Sublicensee pursuant to
Section&nbsp;3.4(a) above shall be subject to the Approved Sublicensee curing all outstanding breaches of the ACY/Neurocrine Standby License the License Agreement and the Sublicense Agreement that
remain uncured and capable of cure by the Approved Sublicensee at the time the ACY/Neurocrine Standby License was terminated within ten (10)&nbsp;business days of the effective date of such
termination and notice from ACY and delineation of the uncured breaches. If the Approved Sublicensee fails to cure such breach within such time period, the license to be granted by ACY to the Approved
Sublicensee under Section&nbsp;3.4(a) above shall automatically be terminated at the end of such ten (10)&nbsp;business day period. Except as set forth above in this Section&nbsp;3.4(b), the
licenses granted by ACY to the Approved Sublicensee under Section&nbsp;3.4(a) above shall be on the terms and conditions set forth in the ACY/Neurocrine Standby License (which shall not include any
payments made or obligations met by Neurocrine or DOV prior to such direct license) and the Approved Sublicensee shall have all of the rights and obligations previously held by Neurocrine thereunder.
Following the Second Effective Time and for so long as the Second ACY Standby License remains in effect, the Approved Sublicensee shall pay directly to ACY all payments and other consideration due
under the Second ACY Standby License. Neurocrine hereby acknowledges and agrees that all amounts paid by the Approved Sublicensee pursuant to the Second ACY Standby License as well as the amounts
referenced in the first sentence of this Section&nbsp;3.4(b) shall be creditable in full against any sums due under the Additional Sublicense Agreement to which the Approved Sublicensee is a party. </FONT></DD></DL>
<BR>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>3.5</B></FONT></DT><DD><FONT SIZE=2><B>Assumed Obligations.</B></FONT><FONT SIZE=2> Notwithstanding any provision to the contrary in this Article&nbsp;3, in no event shall ACY, in granting any of
the rights to Neurocrine under Section&nbsp;3.2 hereof or ACY or DOV to an Approved Sublicensee under Section&nbsp;3.3 or 3.4 hereof, have any obligations (other than the grant of
such licenses) over and above those obligations ACY has under the License Agreement or DOV has under the Sublicense Agreement, in each case as amended by this Agreement.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>3.6</B></FONT></DT><DD><FONT SIZE=2><B>Notices.</B></FONT><FONT SIZE=2> In the event either ACY or DOV provides to the other a notice of breach or of termination under the License Agreement, such
Party shall provide a copy of such notice to Neurocrine and to each Approved Sublicensee with whom Neurocrine has entered into an Additional License Agreement in accordance with the notice provisions
of this Agreement and any Direct License Agreement that may be entered into hereafter. In the event either DOV or Neurocrine provides to the other a notice of breach or of termination under the
Sublicense Agreement, such Party shall provide a copy of such notice to ACY and to each Approved Sublicensee with whom Neurocrine has entered into an Additional License Agreement in accordance with
the notice provisions of this Agreement and any Direct License Agreement that may be entered into hereafter. In the event either Neurocrine or any Approved Sublicensee provides to the other a notice
of breach or of termination under any Additional Sublicense Agreement, Neurocrine shall provide and, where the Approved Sublicensee is the party issuing the notice, shall cause the Approved
Sublicensee to provide a copy of such notice to each of ACY and DOV in accordance with the notice provisions of any Direct License Agreement that may be entered into hereafter. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=8,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5",CHK=328263,FOLIO='8',FILE='DISK009:[03NYC7.03NYC3487]KG3487A.;8',USER='NVILLAL',CD='28-MAR-2003;22:51' -->
<A NAME="page_kg3487_1_9"> </A>
<UL>
<UL>
</UL>
</UL>

<P><FONT SIZE=2><B>4.&nbsp;&nbsp;&nbsp;&nbsp;MISCELLANEOUS.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>4.1</B></FONT></DT><DD><FONT SIZE=2><B>Safety Agreement.</B></FONT><FONT SIZE=2> Upon request of ACY or DOV, each of the Parties shall negotiate and enter into a Safety Agreement to address the
obligations of each of the Parties regarding the reporting of adverse events associated with the use of the Licensed Product. Neurocrine shall likewise obligate each of its Approved Sublicensees to
enter into such an agreement. The terms and conditions of any such safety agreement shall supercede any adverse event reporting obligations set forth in the License Agreement, the Sublicense Agreement
or any Additional Sublicense Agreement.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>4.2</B></FONT></DT><DD><FONT SIZE=2><B>Notices.</B></FONT><FONT SIZE=2> Any notices required hereunder shall be sent by registered or certified mail or by an equivalent service capable of
verification at the address stated below or such other address as to which the parties may provide in the future. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>Wyeth Pharmaceuticals  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="79%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2>If to ACY:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="66%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="66%"><FONT SIZE=2>555 E. Lancaster Ave.<BR>
St. Davids, Pennsylvania 19087<BR>
Attn: Senior Vice President, Global Business Development</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="66%"><FONT SIZE=2><BR>
With a copy to:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="66%"><FONT SIZE=2><BR>
Wyeth<BR>
5 Giralda Farms<BR>
Madison, New Jersey 07940<BR>
Attn: General Counsel</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
If to Neurocrine:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="66%"><FONT SIZE=2><BR>
Neurocrine Biosciences,&nbsp;Inc.<BR>
10555 Science Center Drive<BR>
San Diego, California 92121<BR>
Attn: CEO<BR>
With copy: General Counsel</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
If to DOV:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="66%"><FONT SIZE=2><BR>
DOV Pharmaceutical,&nbsp;Inc.<BR>
433 Hackensack Avenue<BR>
Hackensack, New Jersey 07601<BR>
Attn: CEO<BR>
With copy: General Counsel</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>4.3</B></FONT></DT><DD><FONT SIZE=2><B>Counterparts.</B></FONT><FONT SIZE=2> This Agreement may be executed in any number of counterparts each of which shall be original and all originals of which
shall be deemed a single instrument.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>4.4</B></FONT></DT><DD><FONT SIZE=2><B>Entire Agreement.</B></FONT><FONT SIZE=2> This Agreement, together with the License Agreement and the Sublicense Agreement, each as amended hereby, represents
the full understanding between the Parties with respect to the subject matter hereof and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether
oral or written, among the Parties respecting the subject matter hereof and thereof. Neurocrine shall not become a party to the License Agreement, nor ACY to the Sublicense Agreement, by reason of the
amendment thereto made hereby, and neither Neurocrine nor ACY shall have any right as a result of this Agreement to enforce any provision of the License Agreement or Sublicense Agreement. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=9,SEQ=9,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5",CHK=376034,FOLIO='9',FILE='DISK009:[03NYC7.03NYC3487]KG3487A.;8',USER='NVILLAL',CD='28-MAR-2003;22:51' -->
<A NAME="page_kg3487_1_10"> </A>
<UL>
<UL>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>4.5</B></FONT></DT><DD><FONT SIZE=2><B>No Assignment.</B></FONT><FONT SIZE=2> This Agreement may not be assigned without the prior written consent of each Party hereto except in connection with the
successors of the entire business and assets of the respective Party hereto.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>4.6</B></FONT></DT><DD><FONT SIZE=2><B>Independent Contractors.</B></FONT><FONT SIZE=2> This Agreement shall not constitute any Party as the joint venturer, legal representative or agent of any
other Party hereto and no Party hereto shall have the right or authority to assume or create any obligation on the part of any other Party hereto.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>4.7</B></FONT></DT><DD><FONT SIZE=2><B>Covenant.</B></FONT><FONT SIZE=2> This Agreement shall inure to the benefit of any Approved Sublicensees. Each of the parties undertakes to execute and deliver
a Joinder Agreement in substantially the form annexed hereto as Exhibit&nbsp;A promptly (and in no event later than ten (10)&nbsp;business days) after notification by Neurocrine of the identity of
the specific Approved Sublicensee, whereupon the Approved Sublicensee shall be deemed to be a party to this Agreement as of the Effective Date to the extent set forth in the Joinder Agreement in the
form of Exhibit&nbsp;A hereto. In addition, each of the parties will take any actions including the execution of such additional documents and instruments as may be reasonably necessary to enable an
Approved Sublicensee to enforce its rights hereunder.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>4.8</B></FONT></DT><DD><FONT SIZE=2><B>'621 Patent.</B></FONT><FONT SIZE=2> Without limiting or expanding the definition of ACY Patents in the License Agreement or Patent Rights in the Sublicense
Agreement, the parties each acknowledge that patent US 6,399,621 (the "621 Patent) is an ACY Patent under the License Agreement and a Patent Right under the Sublicense Agreement. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized representatives.</B></FONT></P>

<P><FONT SIZE=2><B>AMERICAN CYANAMID COMPANY  </B></FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="180">

<P><FONT SIZE=2><BR>
By:<BR>
Title: </FONT></P>

<P><FONT SIZE=2><B>NEUROCRINE BIOSCIENCES,&nbsp;INC.  </B></FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="180">

<P><FONT SIZE=2><BR>
By:<BR>
Title: </FONT></P>

<P><FONT SIZE=2><B>DOV PHARMACEUTICAL,&nbsp;INC.  </B></FONT></P>

<P><FONT SIZE=2>/s/&nbsp;&nbsp;</FONT><FONT
SIZE=2>ROBERT HORTON</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="180">

<P><FONT SIZE=2><BR>
By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Robert Horton<BR>
Title:&nbsp;&nbsp;Vice President </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=10,SEQ=10,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5",CHK=200616,FOLIO='10',FILE='DISK009:[03NYC7.03NYC3487]KG3487A.;8',USER='NVILLAL',CD='28-MAR-2003;22:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_ki3487_1_2"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><B>EXHIBIT A  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>[Letterhead
of Neurocrine Biosciences,&nbsp;Inc.] </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ki3487_joinder_agreement"> </A>
<A NAME="toc_ki3487_1"> </A>
<BR></FONT><FONT SIZE=2><B>JOINDER AGREEMENT    <BR>  </B></FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2002 </FONT></P>

<P><FONT SIZE=2>American
Cyanamid Company </FONT></P>

<P><FONT SIZE=2>5
Giralda Farms </FONT></P>

<P><FONT SIZE=2>Madison,
New Jersey 07940 </FONT></P>

<P><FONT SIZE=2>DOV
Pharmaceutical,&nbsp;Inc. </FONT></P>

<P><FONT SIZE=2>433
Hackensack Ave. </FONT></P>


<P><FONT SIZE=2>Hackensack,
New Jersey 07601 </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>Re:</FONT></DT><DD><FONT SIZE=2>Consent
and Agreement, dated December&nbsp;13, 2002, Among American Cyanamid Company, Neurocrine Biosciences,&nbsp;Inc. and DOV Pharmaceutical,&nbsp;Inc. (the "Agreement") </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>Ladies
and Gentlemen: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
terms defined in the Agreement shall when used herein have their defined meanings. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to Section&nbsp;3.1 of the Agreement, Neurocrine acknowledges that it has entered into an Additional Sublicense Agreement with [Name of Approved
Sublicensee] as an Approved Sublicensee. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
this Joinder Agreement, Neurocrine agrees, and each signatory below also agrees, that [Name of Approved Sublicensee] shall be deemed to be a party to the
Agreement effective as of the Effective Date to the extent and solely to the extent that it and shall have all rights and obligations as an Approved Sublicensee under sections 1.1, 2.1, 3.1, 3.3, 3.4,
3.5, 3.6, and 4.1-4.7 of the Agreement. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=2><BR>
Sincerely yours,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="53%" ALIGN="CENTER"><FONT SIZE=2><BR>
NEUROCRINE BIOSCIENCES, INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=2>By</FONT><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<UL>

<P><FONT SIZE=2><I> AGREED TO:  </I></FONT></P>

</UL>

<P><FONT SIZE=2>[NAME
OF APPROVED SUBLICENSEE] </FONT></P>

<P><FONT SIZE=2>By:<BR></FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="144">

<P><FONT SIZE=2>AMERICAN
CYANAMID COMPANY </FONT></P>


<P><FONT SIZE=2>By:<BR></FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="144">

<P><FONT SIZE=2>DOV
PHARMACEUTICAL,&nbsp;INC. </FONT></P>

<P><FONT SIZE=2>By:&nbsp;&nbsp;&nbsp;&nbsp;/s/
Robert Horton<BR></FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="144">
<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=11,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5",CHK=177266,FOLIO='2',FILE='DISK009:[03NYC7.03NYC3487]KI3487A.;10',USER='ARUSS',CD='28-MAR-2003;18:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="03NYC3487_5">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_kg3487_1">CONSENT AND AGREEMENT</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_ki3487_1">JOINDER AGREEMENT</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=WWASSER,SEQ=,EFW="2107125",CP="DOV PHARMACEUTICAL, INC.",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
